DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
968
LY-2382770
2
Antibody
Investigational
Unknown
Unknown
Diabetic Nephropathies
Transforming growth factor beta-1 inhibitor
LY-2382770
×
Maximum Phase:
2
First Approval:
None
UNII:
9TS3G2M6LS
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PIMIVALIMAB
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Non-Small-Cell Lung
Unknown
PIMIVALIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HU3S193
2
Antibody
Investigational
Unknown
Unknown
Colorectal Neoplasms; Lung Neoplasms; Breast Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms
Lewis Y antigen binding agent
HU3S193
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ADINTREVIMAB
2
Antibody
Investigational
Unknown
Unknown
Severe Acute Respiratory Syndrome
Unknown
ADINTREVIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BW250/183
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
BW250/183
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LUCATUMUMAB
2
Antibody
Investigational
Unknown
Unknown
Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Multiple Myeloma
Tumor necrosis factor receptor superfamily member 5 antagonist
LUCATUMUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
P0EP9VFC4R
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
UNASNEMAB
2
Antibody
Investigational
Unknown
Unknown
Spinal Cord Injuries
Unknown
UNASNEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
REMTOLUMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Psoriatic; Arthritis, Rheumatoid
Interleukin 17A inhibitor
REMTOLUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
1V8WRH3RVX
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CANTUZUMAB MERTANSINE
2
Antibody
Investigational
Unknown
Unknown
Unknown
Mucin-1 binding agent
CANTUZUMAB MERTANSINE
×
Maximum Phase:
2
First Approval:
None
UNII:
7Z7EUX7R6M
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
NADECNEMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
NADECNEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
URTOXAZUMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Shiga toxin subunit B inhibitor
URTOXAZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
232D35B3NT
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
SUGEMALIMAB
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Hepatocellular; Neoplasms; Small Cell Lung Carcinoma; Hodgkin Disease; Lymphoma; Carcinoma, Non-Small-Cell Lung; Stomach Neoplasms
Programmed cell death 1 ligand 1 binding agent
SUGEMALIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
90IQR2I6TR
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MIBAVADEMAB
2
Antibody
Investigational
Unknown
Unknown
Lipodystrophy, Congenital Generalized
Unknown
MIBAVADEMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AMG-108
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Diabetes Mellitus; Osteoarthritis
Interleukin-1 receptor antagonist
AMG-108
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AME-133V
2
Antibody
Investigational
Unknown
Unknown
Lymphoma, Non-Hodgkin
Integrin beta-2 inhibitor
AME-133V
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TREGALIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Psoriasis
T-cell surface antigen CD4 agonist
TREGALIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
43D26MK176
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ENOKIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Asthma
Interleukin-9 inhibitor
ENOKIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
I4BE5F78HR
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MAB-425
2
Antibody
Investigational
Unknown
Unknown
Glioma
Epidermal growth factor receptor erbB1 inhibitor
MAB-425
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MM-121
2
Antibody
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Neoplasms; Breast Neoplasms; Fallopian Tube Neoplasms; Ovarian Neoplasms; Peritoneal Neoplasms
Receptor tyrosine-protein kinase erbB-3 antagonist
MM-121
×
Maximum Phase:
2
First Approval:
None
UNII:
1N3L70MDFX
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TNT-1B
2
Antibody
Investigational
Unknown
Unknown
Glioblastoma
DNA-histone H1 complex binding agent
TNT-1B
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HUMAX-IL8
2
Antibody
Investigational
Unknown
Unknown
Neoplasms; Prostatic Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Squamous Cell; Severe Acute Respiratory Syndrome
Interleukin-8 inhibitor
HUMAX-IL8
×
Maximum Phase:
2
First Approval:
None
UNII:
N0YWS8X3S9
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ADUCANUMAB
2
Antibody
Investigational
Unknown
Unknown
Alzheimer Disease
Beta amyloid A4 protein binding agent
ADUCANUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
105J35OE21
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PLOZALIZUMAB
2
Antibody
Investigational
Unknown
Unknown
Melanoma; Atherosclerosis; Cardiovascular Diseases; Diabetic Nephropathies; Multiple Sclerosis
C-C chemokine receptor type 2 inhibitor
PLOZALIZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
4XG66BMN0D
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FLOTETUZUMAB
2
Antibody
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute
Interleukin-3 receptor subunit alpha binding agent
FLOTETUZUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
0AHT0IC02G
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ALXN1007
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
ALXN1007
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
HUMAX-IL15
2
Antibody
Investigational
Unknown
Unknown
Unknown
Lymphocyte differentiation antigen CD38 inhibitor
HUMAX-IL15
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TESIDOLUMAB
2
Antibody
Investigational
Unknown
Unknown
Hemoglobinuria, Paroxysmal; Macular Degeneration; Uveitis, Intermediate; Wet Macular Degeneration
Complement C5 binding agent
TESIDOLUMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
3FO6689MSD
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PG-102
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Psoriatic
Tumor necrosis factor receptor superfamily member 5 inhibitor
PG-102
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ONCOLYSIN CD6
2
Antibody
Investigational
Unknown
Unknown
Unknown
T-cell differentiation antigen CD6 binding agent
ONCOLYSIN CD6
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TENELIXIMAB
2
Antibody
Investigational
Unknown
Unknown
Unknown
Tumor necrosis factor receptor superfamily member 5 partial agonist
TENELIXIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
G0MV33WQ6V
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
KBPA-101
2
Antibody
Investigational
Unknown
Unknown
Pneumonia
Lipopolysaccharide (LPS) inhibitor
KBPA-101
×
Maximum Phase:
2
First Approval:
None
UNII:
62B4OXU259
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
YTTRIUM Y 90 CAPROMAB PENDETIDE
2
Antibody
Investigational
Unknown
Unknown
Unknown
Glutamate carboxypeptidase II binding agent
YTTRIUM Y 90 CAPROMAB PENDETIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ORDESEKIMAB
2
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Celiac Disease; Psoriasis; Vitiligo
Interleukin-15 inhibitor
ORDESEKIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ECROMEXIMAB
2
Antibody
Investigational
Unknown
Unknown
Melanoma
Ganglioside GD3 other
ECROMEXIMAB
×
Maximum Phase:
2
First Approval:
None
UNII:
M76FX2JZRM
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
14,18
2
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
14,18
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
15
16
17
18
19
20
21
…
27
28
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA